ELVN

Enliven Therapeutics, Inc. (ELVN) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics, primarily advancing its lead candidate ELVN-001 (BCR-ABL program) for chronic myeloid leukemia (CML). The company has no approved products and has not generated any revenue to date. It ceased to be an emerging growth company and a smaller reporting company as of December 31, 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Raise: In June 2026, the company completed an underwritten public offering (the "2026 Public Offering"), selling 10.5 million shares and pre-funded warrants for gross proceeds of $460.0 million. This significantly increased total assets from $476.2 million (Dec 31, 2025) to $910.2 million (June 30, 2026).
• R&D Spend Shift: R&D expenses increased due to higher internal costs (stock-based compensation and salaries) and increased external costs for ELVN-001 clinical progression. Conversely, costs for the ELVN-002 program decreased significantly as the company decided to no longer pursue its development to prioritize ELVN-001.
• Stock-Based Compensation: Total stock-based compensation expense rose to $21.3 million for the six months ended June 30, 2026, compared to $14.5 million in the prior year period, driven by modifications to equity awards and higher valuations.
• Interest Income: Other income increased to $8.9 million (YTD 2026) from $6.4 million (YTD 2025), primarily due to a higher investment balance despite lower interest rates.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects its cash, cash equivalents, and marketable securities of $895.2 million to be sufficient to fund operating expenses and capital requirements for at least 12 months from the filing date (August 2026).
• Strategic Focus: The company is prioritizing the advancement of ELVN-001 and preparations for its planned pivotal trial. It is exploring strategic alternatives for the ELVN-002 program and has ceased its development.
• Regulatory Status: ELVN-001 has received Fast Track designation and Orphan Drug designation from the FDA for CML. The company presented positive updated clinical data from the ENABLE trial in June 2026.
• Risks:
  • Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development and commercialization.
  • Geopolitical & Trade: Risks include potential disruptions from conflicts in the Middle East (affecting clinical sites in Israel) and U.S. trade policies/tariffs impacting manufacturing in China and Europe.
  • Regulatory Uncertainty: Changes in FDA leadership, budget, or policy (including the "Unleashing Prosperity Through Deregulation" executive order) could impact review timelines.
  • Competition: The CML market is competitive with six approved BCR-ABL TKIs and several investigational agents.

Investor Verification Checklist

• Verify the timeline and design of the planned ELVN-001 pivotal trial and any recent FDA feedback.
• Confirm the status of the ELVN-002 program and any potential strategic partnerships or asset sales being explored.
• Monitor the impact of U.S. trade tariffs on the cost of manufacturing APIs in China and Europe.
• Review the burn rate relative to the $895.2 million cash position to validate the 12-month liquidity runway.
• Assess the potential dilution from the Sales Agreement (up to $200 million available) and future financing needs.